<DOC>
	<DOCNO>NCT02328118</DOCNO>
	<brief_summary>Proliferative diabetic retinopathy ( PDR ) lead cause visual loss diabetic patient . Operation efficient method treat PDR . Anti-vascular endothelial growth factor ( anti-VEGF ) use adjuvant therapy make operation easy .</brief_summary>
	<brief_title>25-Gauge Vitrectomy With Ranibizumab Triamcinolone Acetonide Proliferative Diabetic Retinopathy China</brief_title>
	<detailed_description>Proliferative diabetic retinopathy ( PDR ) lead cause visual loss diabetic patient . The operation indication include non-absorbed vitreous haemorrhage , dense bleed front macular , proliferative vitreoretinopathy traction macular , tractional retinal detachment combine break , severe progressive fiber vascular proliferation vitreous haemorrhage combine early iris neovascularization . Due VEGF level rise vitreous cavity PDR patient , inflammatory cytokine involve , make easy bleeding surgery heavy inflammatory reaction postoperation , thus affect curative effect operation . Ranibizumab angiogenesis inhibitor , widely apply treatment age-related macular degeneration , recognition ophthalmologist . Some scholar try expand application diabetic macular edema , also obtain good curative effect.Some scholar also apply angiogenesis inhibitor diabetes retinopathy surgery hope reduce occurrence intraoperative bleeding.Compared bevacizumab , short half-life lucentis , thus reduce inhibition VEGF system risk . In project , investigator inject lucentis vitreous cavity surgery PDR , observe effect complication operation , compare triamcinolone acetonide group ( control group ) ; At time cytokine level VEGF , pigment epithelium-derived factor ( PEDF ) , epidermal growth factor ( EGF ) , Transforming Growth Factor-beta ( TGF-beta ) , interleukin 6 ( IL - 6 ) interleukin 8 ( IL - 8 ) detect pretreatment lucentis triamcinolone acetonide , cytokine concentration change compare two group , mechanism PDR clarify theoretical basis look treatment strategy lay .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Type II diabetes mellitus Diabetic Retinopathy Vitreous hemorrhage/Proliferation retinal/Tractional detachment retina Fasting bloodglucose 8mmol/ml Subjects operation vitreous Accompany ophthalmology disease except cataract History vitrectomy surgery study eye Previous subfoveal focal laser photocoagulation study eye Previous participation clinical trial ( either eye ) Previous subfoveal focal laser photocoagulation study eye Other disease afford Vitrectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lucentis</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Triamcinolone Acetonide</keyword>
	<keyword>Vitrectomy</keyword>
	<keyword>PDR</keyword>
</DOC>